Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating and neurodegenerative disease of the central nervous system in young adults. This disorder is a heterogeneous, multifactorial, immune-mediated disease that is influenced by bo
Lampl C, You X, Limmroth V (2012) Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age. Eur J Neurol 19:142-148Lampl C, You X, Limmroth V (2012) Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age. Eur J Neurol 19:142...
MS is an autoimmune disease that affects the central nervous system. Learn more about MS types, causes, symptoms, diagnosis, and treatment.
Multiple sclerosis affects persons of all ages. Age is a predictor of MS phenotypes and onset of relapsing MS (RMS) between age 20 to 40 years accounts for 80% of cases. Secondary progressive MS (SPMS) is considered the long-term outcome of RMS, but more than 30% of people with M...
Secondary Progressive Multiple Sclerosis After years of RRMS, some MS patients begin to accumulate gradually progressive disability, typically slowly worsening gait impairment and incoordination. When a gradually progressive course follows an initially relapsing remitting course, this is referred to as ‘sec...
Multiple Sclerosis Practice Essentials Multiple sclerosis (MS) is an immune-mediated inflammatory disease that attacks myelinated axons in the central nervous system, destroying the myelin and the axon in variable degrees and producing significant physical disability within 20–25 years in more than 30...
T cells, mainly CD4+T cells, are recognised as the primary drivers of multiple sclerosis. Myelin reactive CD4+T cells, that have escaped from a defectiveperipheral tolerance, can be primed after encounteringmolecular mimicry, CNS-sequestered antigens or bystander activation (Rahmanzadeh et al., 20...
Increasing age and disease progression negatively impact remyelination in Multiple Sclerosis. Here authors show that genetically edited human oligodendrocyte precursor cells may help overcome remyelination inhibitors and improve remyelination after transplantation into mouse brain. ...
Fig. 2. Proportions of patients in the indicated relapsing-remitting multiple sclerosis onset age groups in the examined decades. After excluding patients with EOMS and LOMS, the data of the 1,460 remaining patients were analysed; the ages at RRMS onset in this subgroup are shown in Table 2....
Multiple sclerosis (MS) is an immunological disease that causes acute inflammatory lesions and chronic inflammation in the CNS, leading to tissue damage and disability. As awareness of MS has increased and options for therapy have come into use, a large